H.C. Wainwright initiated coverage on ANI Pharma with a new price target
$ANIP
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $50.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 7/10/2025 | $84.00 | Buy | H.C. Wainwright |
| 3/14/2025 | $80.00 | Buy | Jefferies |
| 3/12/2025 | $85.00 | Overweight | Analyst |
| 12/11/2024 | $80.00 | Outperform | Leerink Partners |
| 10/11/2024 | $68.00 | Overweight | Piper Sandler |
| 3/15/2024 | $80.00 | Overweight | CapitalOne |
| 8/22/2023 | $60.00 → $73.00 | Buy | H.C. Wainwright |
| 3/1/2023 | $55.00 | Buy | Guggenheim |
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
10-Q - ANI PHARMACEUTICALS INC (0001023024) (Filer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
Submission status for ANI PHARMS INC's drug HYDROCODONE BITARTRATE AND IBUPROFEN (SUPPL-6) with active ingredient HYDROCODONE BITARTRATE; IBUPROFEN has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 077454, Application Classification: Labeling
Submission status for ANI PHARMS INC's drug OXYCODONE AND ASPIRIN (SUPPL-30) with active ingredient ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE has changed to 'Approval' on 03/04/2021. Application Category: ANDA, Application Number: 040255, Application Classification: Labeling
Submission status for ANI PHARMS INC's drug EZETIMIBE AND SIMVASTATIN (SUPPL-10) with active ingredient EZETIMIBE; SIMVASTATIN has changed to 'Approval' on 02/23/2021. Application Category: ANDA, Application Number: 201890, Application Classification: Labeling
PRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference as follows: Date:Wednesday, June 3, 2026 Time:3:45 p.m. ET Webcast:Click Here The live and archived webcast will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days. About ANI ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Pa
Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin® Gel net revenues of $75.1 million, an increase of 42.1% year-over-yearQuarterly GAAP net income available to common shareholders of $29.5 million; Quarterly adjusted non-GAAP EBITDA of $63.0 million, an increase of 24.1% year-over-yearDiluted GAAP income per share of $1.28 and adjusted non-GAAP diluted earnings per share of $2.05Raised 2026 total net revenue guidance to $1,080 million to $1,140 million, adjusted non-GAAP EBITDA to $285 million to $300 million, and adjusted non-GAAP diluted earnings per share to $9.19 to $9.69; reaffirmed 2026 Cortrophin Gel net revenue guidance of $540 million t
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results. To view the webcast, please click here. Links to access the webcast and conference call will also be available on the "Events & Presentations" page of the Company's website at https://www.anipharmaceuticals.com,
H.C. Wainwright initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $84.00
Jefferies initiated coverage of ANI Pharma with a rating of Buy and set a new price target of $80.00
Analyst initiated coverage of ANI Pharma with a rating of Overweight and set a new price target of $85.00
Quarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin® Gel net revenues of $75.1 million, an increase of 42.1% year-over-yearQuarterly GAAP net income available to common shareholders of $29.5 million; Quarterly adjusted non-GAAP EBITDA of $63.0 million, an increase of 24.1% year-over-yearDiluted GAAP income per share of $1.28 and adjusted non-GAAP diluted earnings per share of $2.05Raised 2026 total net revenue guidance to $1,080 million to $1,140 million, adjusted non-GAAP EBITDA to $285 million to $300 million, and adjusted non-GAAP diluted earnings per share to $9.19 to $9.69; reaffirmed 2026 Cortrophin Gel net revenue guidance of $540 million t
PRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results. To view the webcast, please click here. Links to access the webcast and conference call will also be available on the "Events & Presentations" page of the Company's website at https://www.anipharmaceuticals.com,
Record quarterly and full year net revenues of $247.1 million and $883.4 million, up 29.6% and 43.8% year-over-year, respectivelyTotal Rare Disease quarterly and full year net revenue of $131.3 million and $422.6 million, up 50.8% and 84.1% year-over-year, respectively Quarterly and full year Purified Cortrophin® Gel net revenues of $111.4 million and $347.8 million, up 87.6% and 75.6% year-over-year, respectivelyQuarterly and full year ILUVIEN® and YUTIQ® net revenues of $19.8 million and $74.9 million, respectively(1) Quarterly and full year GAAP net income available to common shareholders of $27.5 million and $77.2 million, respectivelyRecord quarterly and full year adjusted non-GAAP EBIT
SC 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13D/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
SC 13G - ANI PHARMACEUTICALS INC (0001023024) (Subject)
Long time industry leader, Chairman of the Board Patrick Walsh replaces CEO Bill Humphries DURHAM, N.C., Jan. 13, 2025 /PRNewswire/ -- Alcami Corporation ("Alcami"), a leading contract development and manufacturing organization (CDMO), today announced the resignation of Bill Humphries. Alcami's Board Chair and former Chief Executive Officer Patrick Walsh will serve as Interim CEO, ensuring the continuation of smooth operations and a strong client-centric approach from a proven industry veteran. "On behalf of the Board, I'd like to express gratitude to Bill for his leadership
-- Mr. Leonard is an accomplished leader with 35 years of pharmaceuticals and healthcare experience -- Mr. Leonard has significant expertise in pharmacy benefits management, health insurance, and specialty and retail pharmacy -- BAUDETTE, Minn., Aug. 23, 2023 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the addition of Matthew J. Leonard, R.Ph. to its Board of Directors. Mr. Leonard brings more than 35 years of experience as an accomplished leader and innovator within the pharmaceutical industry. This appointment is effective immediately. "We are delighted to add Matthew (Matt) Leonard to our Board of Directors. With his deep leadershi
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) ("ANI" or the "Company") today announced that Krista L. Davis will join the Company as Chief Human Resources Officer, effective September 12. Ms. Davis brings to the Company over 20 years of executive leadership experience in human resources, talent management, and organizational development. "Ms. Davis is an important addition to our leadership team and will bring strategic and innovative thought leadership to our priority people and organizational issues. Krista has a long track record of driving organizational effectiveness and delivering results across industries and cultures, most recently with Novartis, where she led global human resources for